NewAmsterdam Pharma (NAMS) Notes Payables (2022 - 2026)
NewAmsterdam Pharma (NAMS) posted Notes Payables of $50.2 million for Q1 2026, down 12.3% sequentially from $57.3 million in Q4 2025, and up 113.53% YoY from $23.5 million in Q1 2025.
NewAmsterdam Pharma (NAMS) Notes Payables (2022 - 2026) Analysis & Trends
NewAmsterdam Pharma has reported Notes Payables for 5 years, with the latest figure at $50.2 million in Q1 2026.
- Quarterly Notes Payables rose 113.53% year-over-year to $50.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $50.2 million (up 113.53% YoY) and the FY2025 annual result came in at $57.3 million, up 52.67% from the prior year.
- Notes Payables fell to $50.2 million in Q1 2026 per NAMS's latest filing, from $57.3 million in the prior quarter.
- Over five years, Notes Payables peaked at $57.3 million in Q4 2025 and troughed at $3966.7 in Q4 2022.
- A 5-year average of $27.5 million and a median of $23.5 million in 2024 frame the typical range for Notes Payables.
- The sharpest annual moves came in 2023 and 2025: Notes Payables soared 316887.19% in 2023, then retreated 28.85% in 2025.
- Over 5 years, Notes Payables stood at $3966.7 in 2022, then jumped by 316887.19% to $12.6 million in 2023, then surged by 198.35% to $37.5 million in 2024, then jumped by 52.67% to $57.3 million in 2025, then decreased by 12.3% to $50.2 million in 2026.
- According to Business Quant data, Notes Payables over the past three periods registered $50.2 million, $57.3 million, and $44.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | NewAmsterdam Pharma | 3.17 Bn | 3.17 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 54.45 Mn |
| Mar 31, 2026 | 50.23 Mn |
| Dec 31, 2025 | 57.27 Mn |
| Sep 30, 2025 | 44.36 Mn |
| Jun 30, 2025 | 20.93 Mn |
| Mar 31, 2025 | 23.52 Mn |
| Dec 31, 2024 | 37.51 Mn |
| Sep 30, 2024 | 18.90 Mn |
| Jun 30, 2024 | 23.55 Mn |
| Mar 31, 2024 | 33.06 Mn |
| Dec 31, 2023 | 12.57 Mn |
| Jun 30, 2023 | 8.41 Mn |
| Dec 31, 2022 | 3,966.72 |